Invalidity dossier
US 10654929
Added 9/20/2026, 5:16:39 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
US10654929B2 — Antibodies to PD-1 and Uses Thereof
Title: Antibodies to PD-1 and uses thereof
Patent number: US10654929B2
Application number: US15/800,346
Inventors: George Robert Mabry, III; Stephen Sazinsky
Assignee: Jounce Therapeutics, Inc. (current and original)
Priority date: 2016-11-02
Filing date: 2017-11-01
Publication date: 2020-05-19 (application published as US20180118829A1 on 2018-05-03)
Legal status listed: Active, adjusted expiration 2038-06-28
Purpose (plain language): The patent covers antibodies that bind PD-1, a receptor involved in immune regulation, and methods of using them. The classifications place the subject matter in immunoglobulins directed against receptors, cell surface antigens, or cell surface determinants (C07K16/28; C07K16/2818), suggesting a PD-1-directed antibody that can be made as a recombinant protein and formulated for medical use. Listed therapeutic classifications include antineoplastic agents (A61P35/00) and drugs for immunological or allergic disorders (A61P37/00), indicating intended uses in cancer and immune-related conditions.
Scope signals from the text: The prior-art keywords ("antibody," "amino acid sequence," "human") and classifications for human or humanized antibodies (C07K2317/21, C07K2317/24), antibody fragments such as Fab and F(ab')2 (C07K2317/54, C07K2317/55), and constant/Fc region features (C07K2317/52) indicate the disclosure spans antibody formats and sequence-based claims. Related continuations are noted: US16/845,805 (US11384147B2) and US17/834,237 (US11905329B2).
What the excerpt does not establish: It does not provide the claims, amino acid or nucleic acid sequences, figures, examples, or the full specification text. It therefore does not establish specific claim scope, epitope details, binding affinities, dosing, or experimental results. The listed legal status is expressly an assumption, not a legal conclusion. No litigation, ownership-transfer, validity, or prior-art analysis is included.
Source: https://patents.google.com/patent/[US10654929](/patent/US10654929)/en
Generated 10/1/2026, 10:02:59 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 10654929. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.